Cabozantinib

Name: Cabozantinib
Availability: cabozantinib-357379.html

Category:Active Pharmaceutical Ingredients > Other Active Pharmaceutical Ingredients
Product Name:Cabozantinib
CAS No.:849217-68-1
Standard:In-house Standards
Price(USD):Negotiable
Company:Shenzhen Haorui Pharmatech Co., Ltd.

Send Inquiry

Favorites

Similar Products

Curcumin and oyster composite tablets

TOSUFLOXACIN TOSYLATE

PQQ Disodium Salt powder

Pregabalin

Lornoxicam

Linagliptin

Olmesartan Medoxomil

Memantine HCl

3-(naphthalen-1-yl)-N-(3-(4-phenylnaphthalen-1-yl)phenyl)aniline

Pantoprazole Sodium for Injection

Basic Info

Grade: Pharmaceutical Grade

Factory Location: Hubei

Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa
Sample Provided: no

Payment Terms: L/C

Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 for the treatment of hepatocellular carcinoma in previously treated patients.

Send your message to this supplier

From:
To:
Shenzhen Haorui Pharmatech Co., Ltd.
Send a Copy to this Email
Message:
Upload Images / Files
- Supports jpg, jpeg, png,
gif, pdf, doc, docx,
xls, xlsx, txt, rar and zip
- Max upload 3 files;
Max total size: 3MB
(0/3)

Enter between 20 to 4,000 characters.This is not what you are looking for ? Post a Sourcing Request Now
Verification:


Please drag the slider to the right side





 help